生物科技公司Iovance Biotherapeutics, Inc.（IOVA）股价在夜盘交易中暴跌38.49%，主要原因是公司公布的季度业绩大幅低于市场预期。
根据公司最新发布的财报，截至3月31日的季度中，Iovance调整后每股亏损0.36美元，远高于分析师预期的0.24美元亏损。尽管公司营收同比大幅增长6798.5%至4932万美元，但仍远低于分析师预期的8170万美元。此外，公司当季净亏损高达1.1616亿美元，这些数据无疑打击了投资者信心。
值得注意的是，Iovance在过去一个季度的股价已下跌6.0%，今年迄今为止更是下跌了57.7%。尽管华尔街分析师对该公司仍持乐观态度，平均评级为"买入"，并给出18.00美元的12个月目标价，但此次业绩的严重不及预期可能会引发分析师下调评级和目标价。投资者需密切关注未来几天分析师的反应，以及公司管理层对业绩改善的具体措施。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.